{
  "patient_123": {
    "patient_id": "123",
    "test_info": {
      "test_date": "2023-10-15",
      "test_type": "FoundationOne CDx",
      "lab": "Foundation Medicine",
      "specimen_type": "FFPE tumor tissue",
      "tumor_purity": "60%"
    },
    "mutations": [
      {
        "gene": "PIK3CA",
        "variant": "H1047R",
        "variant_type": "SNV",
        "chromosome": "3",
        "position": 178952085,
        "ref": "A",
        "alt": "G",
        "vaf": 0.42,
        "tier": "1",
        "interpretation": "Pathogenic",
        "cosmic_id": "COSM775",
        "clinical_significance": "Activating mutation in PI3K pathway, associated with endocrine therapy resistance"
      },
      {
        "gene": "TP53",
        "variant": "R273H",
        "variant_type": "SNV",
        "chromosome": "17",
        "position": 7577121,
        "ref": "G",
        "alt": "A",
        "vaf": 0.38,
        "tier": "2",
        "interpretation": "Pathogenic",
        "cosmic_id": "COSM10663",
        "clinical_significance": "Hotspot mutation, loss of tumor suppressor function"
      }
    ],
    "copy_number_alterations": [
      {
        "gene": "MYC",
        "alteration": "Amplification",
        "copy_number": 6,
        "interpretation": "Gain"
      }
    ],
    "fusions": [],
    "tmb": {
      "value": 5.2,
      "unit": "mutations/Mb",
      "percentile": 35,
      "interpretation": "TMB-Low"
    },
    "msi_status": "MSS",
    "pdl1": {
      "score": "10%",
      "test": "22C3 pharmDx",
      "interpretation": "Low positive"
    },
    "homologous_recombination_deficiency": {
      "status": "Negative",
      "score": 12
    }
  },
  "patient_456": {
    "patient_id": "456",
    "test_info": {
      "test_date": "2023-09-20",
      "test_type": "FoundationOne CDx",
      "lab": "Foundation Medicine",
      "specimen_type": "FFPE tumor tissue",
      "tumor_purity": "70%"
    },
    "mutations": [
      {
        "gene": "ESR1",
        "variant": "Y537S",
        "variant_type": "SNV",
        "chromosome": "6",
        "position": 152419932,
        "ref": "A",
        "alt": "C",
        "vaf": 0.28,
        "tier": "1",
        "interpretation": "Pathogenic",
        "cosmic_id": "COSM139274",
        "clinical_significance": "Activating mutation causing constitutive ER activation and endocrine resistance"
      }
    ],
    "copy_number_alterations": [
      {
        "gene": "ERBB2",
        "alteration": "Amplification",
        "copy_number": 12,
        "interpretation": "High-level amplification",
        "clinical_significance": "HER2 positive, targetable with trastuzumab, pertuzumab, T-DM1"
      },
      {
        "gene": "CCND1",
        "alteration": "Amplification",
        "copy_number": 8,
        "interpretation": "Amplification"
      }
    ],
    "fusions": [],
    "tmb": {
      "value": 3.1,
      "unit": "mutations/Mb",
      "percentile": 22,
      "interpretation": "TMB-Low"
    },
    "msi_status": "MSS",
    "pdl1": {
      "score": "5%",
      "test": "22C3 pharmDx",
      "interpretation": "Low"
    },
    "homologous_recombination_deficiency": {
      "status": "Negative",
      "score": 8
    }
  },
  "patient_789": {
    "status": "NOT_FOUND",
    "reason": "Genomic testing not ordered - patient just diagnosed, testing pending",
    "recommendation": "Order FoundationOne CDx or similar comprehensive genomic profiling for TNBC. Consider germline BRCA testing given young age and TNBC subtype."
  },
  "patient_234": {
    "patient_id": "234",
    "test_info": {
      "test_date": "2023-09-25",
      "test_type": "Oncotype DX Breast Recurrence Score",
      "lab": "Genomic Health",
      "specimen_type": "FFPE tumor tissue",
      "tumor_purity": "50%"
    },
    "recurrence_score": {
      "value": 18,
      "risk_category": "Intermediate",
      "interpretation": "Intermediate risk of distant recurrence. Chemotherapy benefit uncertain in postmenopausal patients."
    },
    "mutations": [],
    "copy_number_alterations": [],
    "fusions": [],
    "note": "Limited genomic profiling via Oncotype DX (21-gene assay). Full NGS not performed given early stage and low-risk clinical features."
  }
}
